Stockwatch: Specialty Pharma Falling
Executive Summary
If this downbeat first-quarter earnings season has claimed a scalp, it is the business model of specialty pharmaceutical companies. Last week the analysts from Jefferies described the specialty pharmaceutical sector as being in freefall.
You may also be interested in...
Papa's Exit Highlights Perrigo's Shortcomings
After Papa's exit from Perrigo, the company is left to pick up the pieces and is not as strong a business as investors had previously thought.
Teva to buy Allergan Generics; Mylan off the hook but Perrigo still wriggling
Teva Pharmaceutical Industries is to acquire Allergan Generics in a transaction valued at $40.5bn. The news is the culmination of a weekend of rumors that the deal was in the offing. Teva said that as a result of the agreement, it is dropping its pursuit of Mylan. The origin of the majority of Allergan's generic pharmaceuticals is the company formerly known as Actavis.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.